APO Research
Talk to an analyst

APO RESEARCH · REPORT

Quadrivalent Flu Vaccine

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Quadrivalent Flu Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

20 December 2025180 pages

Choose your research edition.

Industry ResearchQuadrivalent Flu Vaccine Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal Quadrivalent Flu Vaccine Industry Growth and Trends Forecast to 203295 pages · $3,450 USDMarket StructureGlobal Quadrivalent Flu Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032180 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Quadrivalent Flu Vaccine Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Quadrivalent Flu Vaccine Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Quadrivalent Flu Vaccine market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Quadrivalent Flu Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Quadrivalent Flu Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Quadrivalent Flu Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Quadrivalent Flu Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Quadrivalent Flu Vaccine include CSL, Sanofi Pasteur, AstraZeneca, GlaxoSmithKline and Abbott, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Quadrivalent Flu Vaccine market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Quadrivalent Flu Vaccine and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Quadrivalent Flu Vaccine sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Quadrivalent Flu Vaccine market size, projected growth trends, production technologies, key applications, and end-use industries.

Quadrivalent Flu Vaccine Segment by Company

CSL

Sanofi Pasteur

AstraZeneca

GlaxoSmithKline

Abbott

Quadrivalent Flu Vaccine Segment by Type

Intramuscular Injection

Nasal Spray

Intradermal Shot

Quadrivalent Flu Vaccine Segment by Application

Clinic

Hospital

Public Health Agency

Other

Quadrivalent Flu Vaccine Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Quadrivalent Flu Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Quadrivalent Flu Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Quadrivalent Flu Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Quadrivalent Flu Vaccine market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Quadrivalent Flu Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Quadrivalent Flu Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Quadrivalent Flu Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Quadrivalent Flu Vaccine Industry Trends Table 2. Quadrivalent Flu Vaccine Industry Drivers Table 3. Quadrivalent Flu Vaccine Industry Opportunities and Challenges Table 4. Quadrivalent Flu Vaccine Industry Restraints Table 5. Global Quadrivalent Flu Vaccine Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Quadrivalent Flu Vaccine Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Quadrivalent Flu Vaccine Sales by Manufacturers (k doses) & (2021-2026) Table 8. Global Quadrivalent Flu Vaccine Sales Market Share by Manufacturers Table 9. Global Quadrivalent Flu Vaccine Average Sales Price (US$/dose) of Manufacturers (2021-2026) Table 10. Global Quadrivalent Flu Vaccine Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Quadrivalent Flu Vaccine Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Quadrivalent Flu Vaccine Manufacturers, Product Type & Application Table 13. Global Quadrivalent Flu Vaccine Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Quadrivalent Flu Vaccine by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Intramuscular Injection Table 17. Major Manufacturers of Nasal Spray Table 18. Major Manufacturers of Intradermal Shot Table 19. Global Quadrivalent Flu Vaccine Sales by Type 2021 VS 2025 VS 2032 (k doses) Table 20. Global Quadrivalent Flu Vaccine Sales by Type (2021-2026) & (k doses) Table 21. Global Quadrivalent Flu Vaccine Sales by Type (2027-2032) & (k doses) Table 22. Global Quadrivalent Flu Vaccine Sales Market Share by Type (2021-2026) Table 23. Global Quadrivalent Flu Vaccine Sales Market Share by Type (2027-2032) Table 24. Global Quadrivalent Flu Vaccine Revenue by Type 2021 VS 2025 VS 2032 (k doses) Table 25. Global Quadrivalent Flu Vaccine Revenue by Type (2021-2026) & (k doses) Table 26. Global Quadrivalent Flu Vaccine Revenue by Type (2027-2032) & (k doses) Table 27. Global Quadrivalent Flu Vaccine Revenue Market Share by Type (2021-2026) Table 28. Global Quadrivalent Flu Vaccine Revenue Market Share by Type (2027-2032) Table 29. Major Manufacturers of Clinic Table 30. Major Manufacturers of Hospital Table 31. Major Manufacturers of Public Health Agency Table 32. Major Manufacturers of Other Table 33. Global Quadrivalent Flu Vaccine Sales by Application 2021 VS 2025 VS 2032 (k doses) Table 34. Global Quadrivalent Flu Vaccine Sales by Application (2021-2026) & (k doses) Table 35. Global Quadrivalent Flu Vaccine Sales by Application (2027-2032) & (k doses) Table 36. Global Quadrivalent Flu Vaccine Sales Market Share by Application (2021-2026) Table 37. Global Quadrivalent Flu Vaccine Sales Market Share by Application (2027-2032) Table 38. Global Quadrivalent Flu Vaccine Revenue by Application 2021 VS 2025 VS 2032 (k doses) Table 39. Global Quadrivalent Flu Vaccine Revenue by Application (2021-2026) & (k doses) Table 40. Global Quadrivalent Flu Vaccine Revenue by Application (2027-2032) & (k doses) Table 41. Global Quadrivalent Flu Vaccine Revenue Market Share by Application (2021-2026) Table 42. Global Quadrivalent Flu Vaccine Revenue Market Share by Application (2027-2032) Table 43. Global Quadrivalent Flu Vaccine Sales by Region: 2021 VS 2025 VS 2032 (k doses) Table 44. Global Quadrivalent Flu Vaccine Sales by Region (2021-2026) & (k doses) Table 45. Global Quadrivalent Flu Vaccine Sales Market Share by Region (2021-2026) Table 46. Global Quadrivalent Flu Vaccine Sales Forecasted by Region (2027-2032) & (k doses) Table 47. Global Quadrivalent Flu Vaccine Sales Forecasted Market Share by Region (2027-2032) Table 48. North America Quadrivalent Flu Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k doses) Table 49. North America Quadrivalent Flu Vaccine Sales by Country (2021-2026) & (k doses) Table 50. North America Quadrivalent Flu Vaccine Sales by Country (2027-2032) & (k doses) Table 51. Europe Quadrivalent Flu Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k doses) Table 52. Europe Quadrivalent Flu Vaccine Sales by Country (2021-2026) & (k doses) Table 53. Europe Quadrivalent Flu Vaccine Sales by Country (2027-2032) & (k doses) Table 54. Asia Pacific Quadrivalent Flu Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k doses) Table 55. Asia Pacific Quadrivalent Flu Vaccine Sales by Country (2021-2026) & (k doses) Table 56. Asia Pacific Quadrivalent Flu Vaccine Sales by Country (2027-2032) & (k doses) Table 57. South America, Middle East and Africa Quadrivalent Flu Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k doses) Table 58. South America, Middle East and Africa Quadrivalent Flu Vaccine Sales by Country (2021-2026) & (k doses) Table 59. South America, Middle East and Africa Quadrivalent Flu Vaccine Sales by Country (2027-2032) & (k doses) Table 60. Global Quadrivalent Flu Vaccine Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 61. Global Quadrivalent Flu Vaccine Revenue by Region (2021-2026) & (US$ Million) Table 62. Global Quadrivalent Flu Vaccine Revenue by Region (2027-2032) & (US$ Million) Table 63. Global Quadrivalent Flu Vaccine Revenue Market Share by Region (2021-2026) Table 64. Global Quadrivalent Flu Vaccine Revenue Market Share by Region (2027-2032) Table 65. CSL Company Information Table 66. CSL Business Overview Table 67. CSL Quadrivalent Flu Vaccine Sales (k doses), Price (US$/dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. CSL Quadrivalent Flu Vaccine Product Portfolio Table 69. CSL Recent Development Table 70. Sanofi Pasteur Company Information Table 71. Sanofi Pasteur Business Overview Table 72. Sanofi Pasteur Quadrivalent Flu Vaccine Sales (k doses), Price (US$/dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Sanofi Pasteur Quadrivalent Flu Vaccine Product Portfolio Table 74. Sanofi Pasteur Recent Development Table 75. AstraZeneca Company Information Table 76. AstraZeneca Business Overview Table 77. AstraZeneca Quadrivalent Flu Vaccine Sales (k doses), Price (US$/dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. AstraZeneca Quadrivalent Flu Vaccine Product Portfolio Table 79. AstraZeneca Recent Development Table 80. GlaxoSmithKline Company Information Table 81. GlaxoSmithKline Business Overview Table 82. GlaxoSmithKline Quadrivalent Flu Vaccine Sales (k doses), Price (US$/dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. GlaxoSmithKline Quadrivalent Flu Vaccine Product Portfolio Table 84. GlaxoSmithKline Recent Development Table 85. Abbott Company Information Table 86. Abbott Business Overview Table 87. Abbott Quadrivalent Flu Vaccine Sales (k doses), Price (US$/dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. Abbott Quadrivalent Flu Vaccine Product Portfolio Table 89. Abbott Recent Development Table 90. Key Raw Materials Table 91. Raw Materials Key Suppliers Table 92. Quadrivalent Flu Vaccine Distributors List Table 93. Quadrivalent Flu Vaccine Customers List Table 94. Research Programs/Design for This Report Table 95. Authors List of This Report Table 96. Secondary Sources Table 97. Primary Sources List of Figures Figure 1. Quadrivalent Flu Vaccine Product Image Figure 2. Global Quadrivalent Flu Vaccine Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Quadrivalent Flu Vaccine Market Size (2021-2032) & (US$ Million) Figure 4. Global Quadrivalent Flu Vaccine Sales (2021-2032) & (k doses) Figure 5. Global Quadrivalent Flu Vaccine Average Price (US$/dose) & (2021-2032) Figure 6. Global Top 5 and 10 Quadrivalent Flu Vaccine Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Intramuscular Injection Image Figure 9. Nasal Spray Image Figure 10. Intradermal Shot Image Figure 11. Global Quadrivalent Flu Vaccine Sales by Type (2021 VS 2025 VS 2032) & (k doses) Figure 12. Global Quadrivalent Flu Vaccine Sales Market Share 2021 VS 2025 VS 2032 Figure 13. Global Quadrivalent Flu Vaccine Sales Market Share by Type (2021-2032) Figure 14. Global Quadrivalent Flu Vaccine Revenue by Type (2021 VS 2025 VS 2032) & (k doses) Figure 15. Global Quadrivalent Flu Vaccine Revenue Market Share 2021 VS 2025 VS 2032 Figure 16. Global Quadrivalent Flu Vaccine Revenue Market Share by Type (2021-2032) Figure 17. Clinic Image Figure 18. Hospital Image Figure 19. Public Health Agency Image Figure 20. Other Image Figure 21. Global Quadrivalent Flu Vaccine Sales by Application (2021 VS 2025 VS 2032) & (k doses) Figure 22. Global Quadrivalent Flu Vaccine Sales Market Share 2021 VS 2025 VS 2032 Figure 23. Global Quadrivalent Flu Vaccine Sales Market Share by Application (2021-2032) Figure 24. Global Quadrivalent Flu Vaccine Revenue by Application (2021 VS 2025 VS 2032) & (k doses) Figure 25. Global Quadrivalent Flu Vaccine Revenue Market Share 2021 VS 2025 VS 2032 Figure 26. Global Quadrivalent Flu Vaccine Revenue Market Share by Application (2021-2032) Figure 27. North America Quadrivalent Flu Vaccine Sales and Growth Rate (2021-2032) & (k doses) Figure 28. North America Quadrivalent Flu Vaccine Sales Market Share by Country (2021-2032) Figure 29. U.S. Quadrivalent Flu Vaccine Sales and Growth Rate (2021-2032) & (k doses) Figure 30. Canada Quadrivalent Flu Vaccine Sales and Growth Rate (2021-2032) & (k doses) Figure 31. Mexico Quadrivalent Flu Vaccine Sales and Growth Rate (2021-2032) & (k doses) Figure 32. Europe Quadrivalent Flu Vaccine Sales and Growth Rate (2021-2032) & (k doses) Figure 33. Europe Quadrivalent Flu Vaccine Sales Market Share by Country (2021-2032) Figure 34. Germany Quadrivalent Flu Vaccine Sales and Growth Rate (2021-2032) & (k doses) Figure 35. France Quadrivalent Flu Vaccine Sales and Growth Rate (2021-2032) & (k doses) Figure 36. U.K. Quadrivalent Flu Vaccine Sales and Growth Rate (2021-2032) & (k doses) Figure 37. Italy Quadrivalent Flu Vaccine Sales and Growth Rate (2021-2032) & (k doses) Figure 38. Netherlands Quadrivalent Flu Vaccine Sales and Growth Rate (2021-2032) & (k doses) Figure 39. Asia Pacific Quadrivalent Flu Vaccine Sales and Growth Rate (2021-2032) & (k doses) Figure 40. Asia Pacific Quadrivalent Flu Vaccine Sales Market Share by Country (2021-2032) Figure 41. China Quadrivalent Flu Vaccine Sales and Growth Rate (2021-2032) & (k doses) Figure 42. Japan Quadrivalent Flu Vaccine Sales and Growth Rate (2021-2032) & (k doses) Figure 43. South Korea Quadrivalent Flu Vaccine Sales and Growth Rate (2021-2032) & (k doses) Figure 44. Southeast Asia Quadrivalent Flu Vaccine Sales and Growth Rate (2021-2032) & (k doses) Figure 45. India Quadrivalent Flu Vaccine Sales and Growth Rate (2021-2032) & (k doses) Figure 46. Australia Quadrivalent Flu Vaccine Sales and Growth Rate (2021-2032) & (k doses) Figure 47. South America, Middle East and Africa Quadrivalent Flu Vaccine Sales and Growth Rate (2021-2032) & (k doses) Figure 48. South America, Middle East and Africa Quadrivalent Flu Vaccine Sales Market Share by Country (2021-2032) Figure 49. Brazil Quadrivalent Flu Vaccine Sales and Growth Rate (2021-2032) & (k doses) Figure 50. South Africa Quadrivalent Flu Vaccine Sales and Growth Rate (2021-2032) & (k doses) Figure 51. Saudi Arabia Quadrivalent Flu Vaccine Sales and Growth Rate (2021-2032) & (k doses) Figure 52. Turkey Quadrivalent Flu Vaccine Sales and Growth Rate (2021-2032) & (k doses) Figure 53. Argentina Quadrivalent Flu Vaccine Sales and Growth Rate (2021-2032) & (k doses) Figure 54. UAE Quadrivalent Flu Vaccine Sales and Growth Rate (2021-2032) & (k doses) Figure 55. Egypt Quadrivalent Flu Vaccine Sales and Growth Rate (2021-2032) & (k doses) Figure 56. Chile Quadrivalent Flu Vaccine Sales and Growth Rate (2021-2032) & (k doses) Figure 57. Global Quadrivalent Flu Vaccine Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Global Quadrivalent Flu Vaccine Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 59. North America Quadrivalent Flu Vaccine Revenue (2021-2032) & (US$ Million) Figure 60. North America Quadrivalent Flu Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Europe Quadrivalent Flu Vaccine Revenue (2021-2032) & (US$ Million) Figure 62. Europe Quadrivalent Flu Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. Asia-Pacific Quadrivalent Flu Vaccine Revenue (2021-2032) & (US$ Million) Figure 64. Asia-Pacific Quadrivalent Flu Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. South America, Middle East and Africa Quadrivalent Flu Vaccine Revenue (2021-2032) & (US$ Million) Figure 66. South America, Middle East and Africa Quadrivalent Flu Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 67. Quadrivalent Flu Vaccine Value Chain Figure 68. Manufacturing Cost Structure Figure 69. Quadrivalent Flu Vaccine Production Mode & Process Figure 70. Direct Comparison with Distribution Share Figure 71. Distributors Profiles Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • Intramuscular Injection
  • Nasal Spray
  • Intradermal Shot
Applications
  • Clinic
  • Hospital
  • Public Health Agency
  • Other
Companies covered
  • CSL
  • Sanofi Pasteur
  • AstraZeneca
  • GlaxoSmithKline
  • Abbott

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Quadrivalent Flu Vaccine Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Quadrivalent Flu Vaccine Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Quadrivalent Flu Vaccine Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Quadrivalent Flu Vaccine Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Quadrivalent Flu Vaccine Market Dynamics
  1. 2.1 Quadrivalent Flu Vaccine Industry Trends
  2. 2.2 Quadrivalent Flu Vaccine Industry Drivers
  3. 2.3 Quadrivalent Flu Vaccine Industry Opportunities and Challenges
  4. 2.4 Quadrivalent Flu Vaccine Industry Restraints
3 Quadrivalent Flu Vaccine Market by Manufacturers
  1. 3.1 Global Quadrivalent Flu Vaccine Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Quadrivalent Flu Vaccine Sales by Manufacturers (2021-2026)
  3. 3.3 Global Quadrivalent Flu Vaccine Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Quadrivalent Flu Vaccine Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Quadrivalent Flu Vaccine Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Quadrivalent Flu Vaccine Manufacturers, Product Type & Application
  7. 3.7 Global Quadrivalent Flu Vaccine Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Quadrivalent Flu Vaccine Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Quadrivalent Flu Vaccine Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Quadrivalent Flu Vaccine Tier 1, Tier 2, and Tier 3
4 Quadrivalent Flu Vaccine Market by Type
  1. 4.1 Quadrivalent Flu Vaccine Type Introduction
  2. 4.1.1 Intramuscular Injection
  3. 4.1.2 Nasal Spray
  4. 4.1.3 Intradermal Shot
  5. 4.2 Global Quadrivalent Flu Vaccine Sales by Type
  6. 4.2.1 Global Quadrivalent Flu Vaccine Sales by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Quadrivalent Flu Vaccine Sales by Type (2021-2032)
  8. 4.2.3 Global Quadrivalent Flu Vaccine Sales Market Share by Type (2021-2032)
  9. 4.3 Global Quadrivalent Flu Vaccine Revenue by Type
  10. 4.3.1 Global Quadrivalent Flu Vaccine Revenue by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Quadrivalent Flu Vaccine Revenue by Type (2021-2032)
  12. 4.3.3 Global Quadrivalent Flu Vaccine Revenue Market Share by Type (2021-2032)
5 Quadrivalent Flu Vaccine Market by Application
  1. 5.1 Quadrivalent Flu Vaccine Application Introduction
  2. 5.1.1 Clinic
  3. 5.1.2 Hospital
  4. 5.1.3 Public Health Agency
  5. 5.1.4 Other
  6. 5.2 Global Quadrivalent Flu Vaccine Sales by Application
  7. 5.2.1 Global Quadrivalent Flu Vaccine Sales by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Quadrivalent Flu Vaccine Sales by Application (2021-2032)
  9. 5.2.3 Global Quadrivalent Flu Vaccine Sales Market Share by Application (2021-2032)
  10. 5.3 Global Quadrivalent Flu Vaccine Revenue by Application
  11. 5.3.1 Global Quadrivalent Flu Vaccine Revenue by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Quadrivalent Flu Vaccine Revenue by Application (2021-2032)
  13. 5.3.3 Global Quadrivalent Flu Vaccine Revenue Market Share by Application (2021-2032)
6 Global Quadrivalent Flu Vaccine Sales by Region
  1. 6.1 Global Quadrivalent Flu Vaccine Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Quadrivalent Flu Vaccine Sales by Region (2021-2032)
  3. 6.2.1 Global Quadrivalent Flu Vaccine Sales by Region (2021-2026)
  4. 6.2.2 Global Quadrivalent Flu Vaccine Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Quadrivalent Flu Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Quadrivalent Flu Vaccine Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Quadrivalent Flu Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Quadrivalent Flu Vaccine Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Quadrivalent Flu Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Quadrivalent Flu Vaccine Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Quadrivalent Flu Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Quadrivalent Flu Vaccine Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Quadrivalent Flu Vaccine Revenue by Region
  1. 7.1 Global Quadrivalent Flu Vaccine Revenue by Region
  2. 7.1.1 Global Quadrivalent Flu Vaccine Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Quadrivalent Flu Vaccine Revenue by Region (2021-2026)
  4. 7.1.3 Global Quadrivalent Flu Vaccine Revenue by Region (2027-2032)
  5. 7.1.4 Global Quadrivalent Flu Vaccine Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Quadrivalent Flu Vaccine Revenue (2021-2032)
  8. 7.2.2 North America Quadrivalent Flu Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Quadrivalent Flu Vaccine Revenue (2021-2032)
  11. 7.3.2 Europe Quadrivalent Flu Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Quadrivalent Flu Vaccine Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Quadrivalent Flu Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Quadrivalent Flu Vaccine Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Quadrivalent Flu Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 CSL
  2. 8.1.1 CSL Company Information
  3. 8.1.2 CSL Business Overview
  4. 8.1.3 CSL Quadrivalent Flu Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 CSL Quadrivalent Flu Vaccine Product Portfolio
  6. 8.1.5 CSL Recent Developments
  7. 8.2 Sanofi Pasteur
  8. 8.2.1 Sanofi Pasteur Company Information
  9. 8.2.2 Sanofi Pasteur Business Overview
  10. 8.2.3 Sanofi Pasteur Quadrivalent Flu Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Sanofi Pasteur Quadrivalent Flu Vaccine Product Portfolio
  12. 8.2.5 Sanofi Pasteur Recent Developments
  13. 8.3 AstraZeneca
  14. 8.3.1 AstraZeneca Company Information
  15. 8.3.2 AstraZeneca Business Overview
  16. 8.3.3 AstraZeneca Quadrivalent Flu Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 AstraZeneca Quadrivalent Flu Vaccine Product Portfolio
  18. 8.3.5 AstraZeneca Recent Developments
  19. 8.4 GlaxoSmithKline
  20. 8.4.1 GlaxoSmithKline Company Information
  21. 8.4.2 GlaxoSmithKline Business Overview
  22. 8.4.3 GlaxoSmithKline Quadrivalent Flu Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 GlaxoSmithKline Quadrivalent Flu Vaccine Product Portfolio
  24. 8.4.5 GlaxoSmithKline Recent Developments
  25. 8.5 Abbott
  26. 8.5.1 Abbott Company Information
  27. 8.5.2 Abbott Business Overview
  28. 8.5.3 Abbott Quadrivalent Flu Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Abbott Quadrivalent Flu Vaccine Product Portfolio
  30. 8.5.5 Abbott Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Quadrivalent Flu Vaccine Value Chain Analysis
  2. 9.1.1 Quadrivalent Flu Vaccine Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Quadrivalent Flu Vaccine Production Mode & Process
  6. 9.2 Quadrivalent Flu Vaccine Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Quadrivalent Flu Vaccine Distributors
  9. 9.2.3 Quadrivalent Flu Vaccine Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst